Cost-Effectiveness of Alcohol Use Disorder Treatment for Alcohol-Associated Liver Disease

Importance: Alcohol-associated liver disease (ALD) is a leading cause of liver-related mortality and liver transplant. Combined behavioral interventions (CBI) and medications for alcohol use disorder (MAUD) are underutilized. Thus, it is critical to identify optimal therapeutic and cost-effective windows for CBI and MAUD in patients with ALD at earlier fibrosis stages. Objective: To evaluate the cost-effectiveness of naltrexone and CBI in preventing cirrhosis in patients with ALD compared with no treatment. Design, Setting, and Participants: This economic evaluation used a Markov state-transition model simulating lifetime disease progression and health care costs associated with ALD. The simulated patient cohort began at 45 years of age with active AUD and stage 3 fibrosis (F3) and could experience progression to compensated or decompensated cirrhosis. Exposure: All patients were assumed to complete a 16-week course of naltrexone along with 52 weeks of CBI. Main Outcomes and Measures: Primary outcomes included total health care cost, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. Secondary outcomes included liver-related mortality and progression to compensated and decompensated cirrhosis. Scenario and sensitivity analyses were performed to determine outcomes at earlier stages and with varied cost and model parameters. Results: Without intervention, 61% of the cohort died from liver-related causes, 88% developed compensated cirrhosis, and 66% of those experienced progression to decompensated cirrhosis, with a lifetime cost of $79 799 per person. With treatment initiated at F3, liver-related mortality was reduced to 58%, lifetime compensated cirrhosis to 87%, and lifetime progression to decompensated cirrhosis to 62%, with a lifetime cost of $78 673. The treatment strategy dominated because the lifetime costs were lower and more QALYs were gained when compared with untreated natural history. Treatment was preferred in sensitivity analyses at relapse rates to 100% and adherence greater than 0%, in scenario analyses when treatment was initiated at stages F2 and F1, and for the models including societal and AUD costs. Conclusions and Relevance: In this economic evaluation of AUD treatment for patients with ALD, treating patients with ALD with naltrexone and CBI at F3 saved cost and was more effective than no treatment, reducing progression to compensated and decompensated cirrhosis. The results remained true at stages F1 and F2 fibrosis and when considering the societal costs and the costs of AUD. Future studies should include prospective evaluations of screening strategies combined with early treatment, as many patients are diagnosed at advanced stages of ALD.

Authors

Institutions

Publication Details

Journal
JAMA Network Open
Published
2026-11-18
DOI
https://doi.org/10.1001/jamanetworkopen.2026.44980
Primary Topic
Alcohol Consumption and Health Effects
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cost-Effectiveness of Alcohol Use Disorder Treatment for Alcohol-Associated Liver Disease

Alice A. Agyekum, Avesh Joseph. Thuluvath, Jeong Yun Yang, Elizabeth C. Verna et al.
2 links
JAMA Network Open
Alcohol Consumption and Health Effects
article

Cost-Effectiveness of Alcohol Use Disorder Treatment for Alcohol-Associated Liver Disease

Alice A. Agyekum, Avesh Joseph. Thuluvath, Jeong Yun Yang, Elizabeth C. Verna, Gene Young Im, Chin Hur, Sheril Varghese, Cadence Chang, Annabel Gerber
article en

Abstract

Importance: Alcohol-associated liver disease (ALD) is a leading cause of liver-related mortality and liver transplant. Combined behavioral interventions (CBI) and medications for alcohol use disorder (MAUD) are underutilized. Thus, it is critical to identify optimal therapeutic and cost-effective windows for CBI and MAUD in patients with ALD at earlier fibrosis stages. Objective: To evaluate the cost-effectiveness of naltrexone and CBI in preventing cirrhosis in patients with ALD compared with no treatment. Design, Setting, and Participants: This economic evaluation used a Markov state-transition model simulating lifetime disease progression and health care costs associated with ALD. The simulated patient cohort began at 45 years of age with active AUD and stage 3 fibrosis (F3) and could experience progression to compensated or decompensated cirrhosis. Exposure: All patients were assumed to complete a 16-week course of naltrexone along with 52 weeks of CBI. Main Outcomes and Measures: Primary outcomes included total health care cost, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. Secondary outcomes included liver-related mortality and progression to compensated and decompensated cirrhosis. Scenario and sensitivity analyses were performed to determine outcomes at earlier stages and with varied cost and model parameters. Results: Without intervention, 61% of the cohort died from liver-related causes, 88% developed compensated cirrhosis, and 66% of those experienced progression to decompensated cirrhosis, with a lifetime cost of $79 799 per person. With treatment initiated at F3, liver-related mortality was reduced to 58%, lifetime compensated cirrhosis to 87%, and lifetime progression to decompensated cirrhosis to 62%, with a lifetime cost of $78 673. The treatment strategy dominated because the lifetime costs were lower and more QALYs were gained when compared with untreated natural history. Treatment was preferred in sensitivity analyses at relapse rates to 100% and adherence greater than 0%, in scenario analyses when treatment was initiated at stages F2 and F1, and for the models including societal and AUD costs. Conclusions and Relevance: In this economic evaluation of AUD treatment for patients with ALD, treating patients with ALD with naltrexone and CBI at F3 saved cost and was more effective than no treatment, reducing progression to compensated and decompensated cirrhosis. The results remained true at stages F1 and F2 fibrosis and when considering the societal costs and the costs of AUD. Future studies should include prospective evaluations of screening strategies combined with early treatment, as many patients are diagnosed at advanced stages of ALD.

JAMA Network OpenVol. 9(11)
Columbia University Irving Medical Center (US)
Good health and well-being
Alcohol Consumption and Health Effects
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon